This hypothesis could also explain the absence of TP53 point mutations, which are generally considered late events in colorectal carcinogenesis [65], and the relative scarcity of CTNNB1-activating point mutations in the incident CRC of our study, which were mostly of low stage. The gene discussed is TP53; the disease is medical procedure.